Cardiovascular Health

Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.

Investigational anti-amyloid monoclonal antibodies may offer a novel pathway to disease reversal.

HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.

A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.

A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.

A new device and expanded label tie LDL-C lowering to reduced cardiovascular risk.

New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.

Pharmacists are well equipped to manage DOAC therapy by providing initial education, adherence support, and safety monitoring.

A real-world analysis of matched adults links glucagon-like peptide-1 (GLP-1) receptor agonist use to fewer major cardiovascular events, driven by a mortality benefit.

Stacey Cutrell, PharmD, BCACP, CDCES, on the PREVENT calculator, screening for secondary causes, intensive BP targets, and fixing stubborn blood pressure.

Tracking 3-year changes in the heart stress marker separated older adults whose risk climbed from those whose risk resolved.

New ACC statement urges pharmacists to weigh cognition and frailty in every older adult's cardiovascular regimen.

Pharmacists can educate patients on preventive measures to avoid heat-related illnesses.

A US claims analysis found a 32% relative reduction in major adverse cardiovascular events (MACE) with tirzepatide vs a placebo-proxy comparator.

Although weight loss is a primary goal, the ultimate utility of these agents lies in their ability to reduce long-term morbidity.

SHASTA-3 and SHASTA-4 also showed a statistically significant drop in acute pancreatitis events, supporting a planned US sNDA this year.

New scientific statement links moderate caffeine to lower cardiovascular risk—but flags energy drinks as a distinct hazard pharmacists should counsel on.

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP, led a Pharmacy Times Clinical Forum on optimizing the management of patients with heart failure across practice settings.

Pharmacists proactively identify red flags for early detection, navigate complex insurance and access barriers for high-cost disease-modifying therapies, and serve as educators across settings.

The 20-mg once-daily tablet is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C).

A simplified, no-cost machine learning version of the Martin-Hopkins equation matched the original's accuracy across millions of blood samples, helping clinicians identify patients who qualify for lipid-lowering therapy.

A member of the cardio-kidney-metabolic syndrome (CKM) guideline writing committee outlines steps pharmacists can take to ensure the kidney component of CKM is not overlooked.

These recommendations for acute pulmonary embolism management are most applicable to pharmacists on the interdisciplinary team managing acute PE.

Wendy St Peter, PharmD, explains how the new cardio-kidney-metabolic (CKM) syndrome guideline supports pharmacist-led medication management, staging tools, and deprescribing.

By targeting aldosterone synthesis directly, baxdrostat offers a novel mechanism for addressing resistant hypertension.